Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(1.99)
# 2,968
Out of 4,876 analysts
52
Total ratings
30.36%
Success rate
-1.45%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPRX Eupraxia Pharmaceuticals | Initiates: Buy | $12 | $5.30 | +126.42% | 2 | Jun 26, 2025 | |
| CNTB Connect Biopharma Holdings | Assumes: Buy | $7 | $1.00 | +600.00% | 1 | Jun 12, 2025 | |
| PYPD PolyPid | Maintains: Buy | $11 → $13 | $3.57 | +264.15% | 3 | Jun 9, 2025 | |
| HRTX Heron Therapeutics | Initiates: Buy | $6 | $2.14 | +180.37% | 2 | Jun 9, 2025 | |
| MIST Milestone Pharmaceuticals | Assumes: Buy | $5 | $1.86 | +168.82% | 2 | Jun 5, 2025 | |
| CRDL Cardiol Therapeutics | Initiates: Buy | $9 | $1.41 | +538.30% | 1 | Jun 2, 2025 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $21 | $5.62 | +273.67% | 2 | May 28, 2025 | |
| RMTI Rockwell Medical | Initiates: Buy | $5 | $0.79 | +531.23% | 1 | Nov 14, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $12 | $2.23 | +438.12% | 1 | Nov 14, 2024 | |
| OMER Omeros | Initiates: Buy | $9 | $3.20 | +181.25% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.34 | +2,287.35% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $6.35 | +151.97% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $12.50 | +4.00% | 1 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $3.76 | +112.77% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.55 | +1,711.59% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $6.05 | +7,420.66% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $28.41 | +107.67% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $106.90 | +68.38% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $0.58 | +3,683.32% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $7.14 | +26.05% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $28.81 | +11.07% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.82 | +1,208,691.21% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $22 | $29.93 | -26.50% | 5 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $78 → $40 | $65.50 | -38.93% | 3 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $14.09 | +254.86% | 1 | Jul 12, 2018 |
Eupraxia Pharmaceuticals
Jun 26, 2025
Initiates: Buy
Price Target: $12
Current: $5.30
Upside: +126.42%
Connect Biopharma Holdings
Jun 12, 2025
Assumes: Buy
Price Target: $7
Current: $1.00
Upside: +600.00%
PolyPid
Jun 9, 2025
Maintains: Buy
Price Target: $11 → $13
Current: $3.57
Upside: +264.15%
Heron Therapeutics
Jun 9, 2025
Initiates: Buy
Price Target: $6
Current: $2.14
Upside: +180.37%
Milestone Pharmaceuticals
Jun 5, 2025
Assumes: Buy
Price Target: $5
Current: $1.86
Upside: +168.82%
Cardiol Therapeutics
Jun 2, 2025
Initiates: Buy
Price Target: $9
Current: $1.41
Upside: +538.30%
Trevi Therapeutics
May 28, 2025
Initiates: Buy
Price Target: $21
Current: $5.62
Upside: +273.67%
Rockwell Medical
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $0.79
Upside: +531.23%
Achieve Life Sciences
Nov 14, 2024
Initiates: Buy
Price Target: $12
Current: $2.23
Upside: +438.12%
Omeros
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $3.20
Upside: +181.25%
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.34
Upside: +2,287.35%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $6.35
Upside: +151.97%
Aug 26, 2024
Initiates: Buy
Price Target: $13
Current: $12.50
Upside: +4.00%
Jun 13, 2024
Initiates: Buy
Price Target: $8
Current: $3.76
Upside: +112.77%
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $0.55
Upside: +1,711.59%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $6.05
Upside: +7,420.66%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $28.41
Upside: +107.67%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $106.90
Upside: +68.38%
Dec 5, 2022
Maintains: Overweight
Price Target: $30 → $22
Current: $0.58
Upside: +3,683.32%
Feb 25, 2022
Initiates: Overweight
Price Target: $9
Current: $7.14
Upside: +26.05%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $28.81
Upside: +11.07%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.82
Upside: +1,208,691.21%
Aug 6, 2021
Downgrades: Neutral
Price Target: $30 → $22
Current: $29.93
Upside: -26.50%
May 7, 2020
Downgrades: Neutral
Price Target: $78 → $40
Current: $65.50
Upside: -38.93%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $14.09
Upside: +254.86%